This new report will help you and/or your team build deep business acumen about the channels for traditional and specialty drugs. I packed enough into the report to make it valuable whether you’re new to the industry or a grizzled veteran.
This year’s report is 126 pages—49 pages longer than the 2010-11 report. It includes expanded coverage of the specialty pharmaceutical channels (hence the new title), a new chapter on wholesaler profitability, and more detailed company analysis of the Big Three public wholesalers—AmerisourceBergen, McKesson, and Cardinal Health. All information is updated through mid-2011, including 55 data-packed exhibits (vs. only 31 exhibits in the 2010-11 edition).
I worked hard to make The 2011-12 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors into a comprehensive, forward-looking reference. I hope you enjoy reading it as much as I enjoyed writing it!
The report analyzes today's marketplace economics and examines key trends for the future. You can see the breadth and depth of content by reviewing the Table of Contents, List of Exhibits, or a free Overview of the Report. If you still have questions, please feel free to email me.
My target audience is diverse:
- Pharmaceutical manufacturers (Pembroke's primary consulting clients, BTW)
- Pharmaceutical wholesalers
- Buyers and executives at retail and institutional pharmacies of all sizes
- Investors in the public companies
- Pharmacy Benefit Managers (PBMs)
- Policy analysts
True Drug Channels wonks will also appreciate the report's 146 endnotes. (Yes, really.) In keeping with the spirit of this website, I include clickable weblinks to the primary sources whenever available.